SAN DIEGO , Oct. 23, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that John Fair , Chief Business Officer, will present at the Dawson James Securities 4th Annual Small Cap Growth Conference on Tuesday, October
SAN DIEGO , Oct. 15, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s health-focused biopharmaceutical company, today announced it will be presenting scientific and technical details on its innovative intra-vaginal ring (IVR) technologies at the Partnership
SAN DIEGO , Oct. 10, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that Sabrina Martucci Johnson , President and Chief Executive Officer, will present at the 2018 BIO Investor Forum on Wednesday, October 17, 2018
SAN DIEGO , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced the appointment of Greg Matz to its board of directors. Most recently, Mr. Matz served as the Senior Vice President and Chief Financial Officer
Update on recent discussions with the FDA on the Topical 5% Sildenafil Citrate Cream for Female Sexual Arousal Disorder, and on other protofolio programs SAN DIEGO , Aug. 30, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today
SAN DIEGO , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that John Fair , Chief Business Officer, will present at the Canaccord Genuity 38th Annual Growth Conference on Thursday, August 9, 2018 at 1:00
CatSper antagonist has potential to provide pregnancy prevention via administration to either women or men as a novel, rapidly reversible, non-hormonal contraceptive SAN DIEGO , July 16, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience , Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical
SAN DIEGO , June 06, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced the appointment of David Friend , Ph.D., to the newly created role of Chief Scientific Officer (CSO). “We are excited to add Dr.
SAN DIEGO , June 04, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced the appointment of Mary Jarosz , RPh, to the newly created role of Global Head of Regulatory Affairs.
SAN DIEGO , May 16, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company focused on women’s sexual and reproductive health, announced today that President and CEO Sabrina Martucci Johnson is a finalist for the Entrepreneur Of The Year ®
